WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406805
CAS#: 211555-05-4
Description: WHI-P97 is a JAK3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays. WHI-P97 effectively inhibited the in vitro invasiveness of EGFR-positive human cancer cells in a concentration-dependent manner.
Hodoodo Cat#: H406805
Name: WHI-P97
CAS#: 211555-05-4
Chemical Formula: C16H13Br2N3O3
Exact Mass: 452.93
Molecular Weight: 455.106
Elemental Analysis: C, 42.23; H, 2.88; Br, 35.11; N, 9.23; O, 10.55
Synonym: WHI-P97; WHI-P 97; WHI-P 97; WHIP 97; WHIP97; WHIP-97
IUPAC/Chemical Name: 2,6-dibromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
InChi Key: YVCXQRVVNQMZEI-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H13Br2N3O3/c1-23-13-5-9-12(6-14(13)24-2)19-7-20-16(9)21-8-3-10(17)15(22)11(18)4-8/h3-7,22H,1-2H3,(H,19,20,21)
SMILES Code: OC1=C(Br)C=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 455.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ji KA, Yang MS, Jou I, Shong MH, Joe EH. Thrombin induces expression of cytokine-induced SH2 protein (CIS) in rat brain astrocytes: involvement of phospholipase A2, cyclooxygenase, and lipoxygenase. Glia. 2004 Nov 1;48(2):102-11. PubMed PMID: 15378659.
2: Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta. 2004 Mar 11;1697(1-2):53-69. Review. PubMed PMID: 15023350.
3: Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001 May;1(1):59-71. Review. PubMed PMID: 12188892.
4: Sudbeck EA, Ghosh S, Liu XP, Zheng Y, Myers DE, Uckun FM. Tyrosine kinase inhibitors against EGF receptor-positive malignancies. Methods Mol Biol. 2001;166:193-218. Review. PubMed PMID: 11217368.
5: Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec;295(3):912-26. PubMed PMID: 11082424.
6: Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. Anticancer Drug Des. 1999 Oct;14(5):403-10. PubMed PMID: 10766295.
7: Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82. PubMed PMID: 10389946.